Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA

S. Oh; E. Kim; D. Kang; M. Kim; J. H. Kim; J. J. Song

doi:10.1038/cgt.2012.90

Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA

S. Oh, E. Kim, D. Kang, M. Kim, J. H. Kim, J. J. Song

Department of Radiology

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Tumor cells secrete a variety of cytokines to outgrow and evade host immune surveillance. In this context, transforming growth factor-β1 (TGF-β1) is an extremely interesting cytokine because it has biphasic effects in cancer cells and normal cells. TGF-β1 acts as a growth inhibitor in normal cells, whereas it promotes tumor growth and progression in tumor cells. Overexpression of TGF-β1 in tumor cells also provides additional oncogenic activities by circumventing the host immune surveillance. Therefore, this study ultimately aimed to test the hypothesis that suppression of TGF-β1 in tumor cells by RNA interference can have antitumorigenic effects. However, we demonstrated here that the interrelation between TGF-β isotypes should be carefully considered for the antitumor effect in addition to the selection of target sequences with highest efficacy. The target sequences were proven to be highly specific and effective for suppressing both TGF-β1 mRNA and protein expression in cells after infection with an adenovirus expressing TGF-β1 short hairpin RNA (shRNA). A single base pair change in the shRNA sequence completely abrogated the suppressive effect on TGF-β1. Surprisingly, the suppression of TGF-β1 induced TGF-β3 upregulation, and the suppression of TGF-β2 induced another unexpected downregulation of both TGF-β1 and TGF-β3. Taken together, this information may prove useful when considering the design for a novel cancer immunogene therapy.

Original language	English
Pages (from-to)	94-100
Number of pages	7
Journal	Cancer Gene Therapy
Volume	20
Issue number	2
DOIs	https://doi.org/10.1038/cgt.2012.90
Publication status	Published - 2013 Feb

Bibliographical note

Funding Information:
This work was supported by the Industrial Strategic Technology Development program (10035562: Development of nucleic acid-based anticancer drugs overcoming the immunotherapy resistance) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education. Science and Technology (2012-0002108). S Oh and E Kim are funded by the Brain Korea 21 project for Medical Science, Yonsei University, College of Medicine, Seoul, South Korea.

All Science Journal Classification (ASJC) codes

Molecular Medicine
Molecular Biology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/cgt.2012.90

Cite this

@article{d223021b734042018ec8cafca4af776a,

title = "Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA",

abstract = "Tumor cells secrete a variety of cytokines to outgrow and evade host immune surveillance. In this context, transforming growth factor-β1 (TGF-β1) is an extremely interesting cytokine because it has biphasic effects in cancer cells and normal cells. TGF-β1 acts as a growth inhibitor in normal cells, whereas it promotes tumor growth and progression in tumor cells. Overexpression of TGF-β1 in tumor cells also provides additional oncogenic activities by circumventing the host immune surveillance. Therefore, this study ultimately aimed to test the hypothesis that suppression of TGF-β1 in tumor cells by RNA interference can have antitumorigenic effects. However, we demonstrated here that the interrelation between TGF-β isotypes should be carefully considered for the antitumor effect in addition to the selection of target sequences with highest efficacy. The target sequences were proven to be highly specific and effective for suppressing both TGF-β1 mRNA and protein expression in cells after infection with an adenovirus expressing TGF-β1 short hairpin RNA (shRNA). A single base pair change in the shRNA sequence completely abrogated the suppressive effect on TGF-β1. Surprisingly, the suppression of TGF-β1 induced TGF-β3 upregulation, and the suppression of TGF-β2 induced another unexpected downregulation of both TGF-β1 and TGF-β3. Taken together, this information may prove useful when considering the design for a novel cancer immunogene therapy.",

author = "S. Oh and E. Kim and D. Kang and M. Kim and Kim, {J. H.} and Song, {J. J.}",

note = "Funding Information: This work was supported by the Industrial Strategic Technology Development program (10035562: Development of nucleic acid-based anticancer drugs overcoming the immunotherapy resistance) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education. Science and Technology (2012-0002108). S Oh and E Kim are funded by the Brain Korea 21 project for Medical Science, Yonsei University, College of Medicine, Seoul, South Korea.",

year = "2013",

month = feb,

doi = "10.1038/cgt.2012.90",

language = "English",

volume = "20",

pages = "94--100",

journal = "Cancer Gene Therapy",

issn = "0929-1903",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA

AU - Oh, S.

AU - Kim, E.

AU - Kang, D.

AU - Kim, M.

AU - Kim, J. H.

AU - Song, J. J.

N1 - Funding Information: This work was supported by the Industrial Strategic Technology Development program (10035562: Development of nucleic acid-based anticancer drugs overcoming the immunotherapy resistance) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education. Science and Technology (2012-0002108). S Oh and E Kim are funded by the Brain Korea 21 project for Medical Science, Yonsei University, College of Medicine, Seoul, South Korea.

PY - 2013/2

Y1 - 2013/2

N2 - Tumor cells secrete a variety of cytokines to outgrow and evade host immune surveillance. In this context, transforming growth factor-β1 (TGF-β1) is an extremely interesting cytokine because it has biphasic effects in cancer cells and normal cells. TGF-β1 acts as a growth inhibitor in normal cells, whereas it promotes tumor growth and progression in tumor cells. Overexpression of TGF-β1 in tumor cells also provides additional oncogenic activities by circumventing the host immune surveillance. Therefore, this study ultimately aimed to test the hypothesis that suppression of TGF-β1 in tumor cells by RNA interference can have antitumorigenic effects. However, we demonstrated here that the interrelation between TGF-β isotypes should be carefully considered for the antitumor effect in addition to the selection of target sequences with highest efficacy. The target sequences were proven to be highly specific and effective for suppressing both TGF-β1 mRNA and protein expression in cells after infection with an adenovirus expressing TGF-β1 short hairpin RNA (shRNA). A single base pair change in the shRNA sequence completely abrogated the suppressive effect on TGF-β1. Surprisingly, the suppression of TGF-β1 induced TGF-β3 upregulation, and the suppression of TGF-β2 induced another unexpected downregulation of both TGF-β1 and TGF-β3. Taken together, this information may prove useful when considering the design for a novel cancer immunogene therapy.

AB - Tumor cells secrete a variety of cytokines to outgrow and evade host immune surveillance. In this context, transforming growth factor-β1 (TGF-β1) is an extremely interesting cytokine because it has biphasic effects in cancer cells and normal cells. TGF-β1 acts as a growth inhibitor in normal cells, whereas it promotes tumor growth and progression in tumor cells. Overexpression of TGF-β1 in tumor cells also provides additional oncogenic activities by circumventing the host immune surveillance. Therefore, this study ultimately aimed to test the hypothesis that suppression of TGF-β1 in tumor cells by RNA interference can have antitumorigenic effects. However, we demonstrated here that the interrelation between TGF-β isotypes should be carefully considered for the antitumor effect in addition to the selection of target sequences with highest efficacy. The target sequences were proven to be highly specific and effective for suppressing both TGF-β1 mRNA and protein expression in cells after infection with an adenovirus expressing TGF-β1 short hairpin RNA (shRNA). A single base pair change in the shRNA sequence completely abrogated the suppressive effect on TGF-β1. Surprisingly, the suppression of TGF-β1 induced TGF-β3 upregulation, and the suppression of TGF-β2 induced another unexpected downregulation of both TGF-β1 and TGF-β3. Taken together, this information may prove useful when considering the design for a novel cancer immunogene therapy.

UR - http://www.scopus.com/inward/record.url?scp=84874111849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874111849&partnerID=8YFLogxK

U2 - 10.1038/cgt.2012.90

DO - 10.1038/cgt.2012.90

M3 - Article

C2 - 23306609

AN - SCOPUS:84874111849

SN - 0929-1903

VL - 20

SP - 94

EP - 100

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

IS - 2

ER -

Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this